Advertisement
U.S. markets open in 9 hours 20 minutes

Eagle Pharmaceuticals, Inc. (EGRX)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
5.62-0.43 (-7.11%)
At close: 04:00PM EDT
5.55 -0.07 (-1.25%)
After hours: 05:43PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Momentum

Momentum

Previous Close6.05
Open5.95
Bid5.87 x 1100
Ask5.87 x 800
Day's Range5.54 - 6.19
52 Week Range4.10 - 32.44
Volume143,363
Avg. Volume246,720
Market Cap72.825M
Beta (5Y Monthly)0.43
PE Ratio (TTM)6.61
EPS (TTM)0.85
Earnings DateMay 07, 2024 - May 13, 2024
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Undervalued
38% Est. Return

Subscribe to Yahoo Finance Plus to view Fair Value for EGRX

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Eagle Pharmaceuticals, Inc.
    EGRX: Lowering target price to $19.00EAGLE PHARMACEUTICALS INC has an Investment Rating of HOLD; a target price of $19.000000; an Industry Subrating of Medium; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of High.
    Rating
    Fair Value
    Economic Moat
    9 months agoArgus Research
View more
  • GlobeNewswire

    Eagle Pharmaceuticals Provides Update on Bendamustine Intellectual Property Portfolio

    WOODCLIFF LAKE, N.J., Jan. 18, 2024 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today provided an update on its bendamustine intellectual property portfolio. On January 16, 2024, the United States Court of Appeals for the Federal Circuit affirmed the previously announced decision by the United States District Court for the District of Delaware finding that the 505(b)(2) drug applications referencing BELRAPZO® filed by Slayback Pharma Limited Liabilit

  • GlobeNewswire

    Eagle Pharmaceuticals to Present Abstract on Post-hoc Analysis of Amisulpride at the 77th PGA (PostGraduate Assembly in Anesthesiology) in New York City

    Barhemsys Barhemsys -- BARHEMSYS® (amisulpride) Injection is the first and only antiemetic approved by the U.S. Food and Drug Administration (“FDA”) for rescue treatment of postoperative nausea and vomiting (“PONV”) despite prophylaxis1 and is also approved for the treatment of PONV in patients who have not received prophylaxis and for the prevention of PONV -- -- In patients who experience PONV, the incidence of nausea is substantially greater than the incidence of vomiting2,3 -- -- This post-h

  • GlobeNewswire

    Eagle Pharmaceuticals Announces Receipt of Notification of Deficiency from Nasdaq Regarding Requirement to Timely File Quarterly Report on Form 10-Q

    WOODCLIFF LAKE, N.J., Nov. 29, 2023 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (the “Company”) today announced that it received a notice (the “Notice”) on November 27, 2023 from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) advising the Company that it is not currently in compliance with Nasdaq’s continued listing requirements under the Nasdaq Listing Rule 5250(c)(1) (the “Rule”), which requires timely filing of all required periodic financia